Page 93 - Read Online

Cross et al. J Cancer Metastasis Treat 2021;7:55 https://dx.doi.org/10.20517/2394-4722.2021.99 Page 9 of 9

metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6. DOI PubMed
7. Choueiri TK, Bukowski RM, Rini BI. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol
2006;33:596-606. DOI PubMed
8. Heng DY, Kollmannsberger C. State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol 2009;16 Suppl 1:S16-23.
DOI PubMed PMC
9. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal
cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60-6. DOI PubMed
10. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell
Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141-8. DOI PubMed PMC
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with
advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40. DOI PubMed
12. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma:
results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66:704-10. DOI PubMed
13. Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or
without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol 2016;34:3267-75. DOI PubMed PMC
14. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous
metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5:164-70. DOI
PubMed PMC
15. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med
2018;379:417-27. DOI PubMed
16. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell
carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079. DOI PubMed PMC
17. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of
advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol
2020;21:1563-73. DOI PubMed